Drugmaker Kiniksa's Q2 revenue jumps 52%

Kiniksa Pharmaceuticals International

29/07/2025 12:36

Overview

Kiniksa Q2 2025 ARCALYST revenue grows 52% yr/yr to $156.8 mln

Kiniksa initiates Phase 2/3 trial for KPL-387 in recurrent pericarditis

Outlook

Kiniksa raises 2025 ARCALYST revenue guidance to $625-$640 mln

Company expects KPL-387 Phase 2 trial data in second half of 2026

Company expects annual cash flow to remain positive

Result Drivers

ARCALYST PENETRATION - Expanded penetration in recurrent pericarditis market drives 52% yr/yr revenue growth

PRESCRIBER GROWTH - Increase in both new and repeat prescribers supports ARCALYST sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$156.80 mln
Q2 EPS
$0.24
Q2 Net Income
$17.83 mln
Q2 Operating Expenses
$136.64 mln
Q2 Pretax Profit
$22.88 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International PLC is $40.00, about 32.4% above its July 28 closing price of $27.04

The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 33 three months ago

Press Release: ID:nGNX6BK20g

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)